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ABSTRACT

Disclosed herein are novel methods for screening for compounds useful in treating telomerase positive cancers. In
exemplary embodiments, screening methods are based on the
implementation or manipulation of therapeutic agents that
up-regulate activity or expression ofMKRN polypeptides or
polynucleotides encoding the same, respectively. The methods are useful in identifying agents that can serve as cancer
therapeutic agents.
1 Claim, 5 Drawing Sheets
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either alone or before treatment with GA. (B) Concentration
dependence of GA on hTERT. H1299 cells transfected with
Flag-hTERT or hTERT-HA were treated for 2 hours with the
GA concentration indicated. The hTERT polypeptides were
visualized with anti-Flag or anti-HA antibodies as marked by
each blot. (C) Down-regulation of endogenous hTERT by
GA. H1299 cells were treated with 0.1 µM GA for the indicated times, and cell lysates were analyzed by immunoprecipitation with anti-hTERT antibody followed by immunoblotting using same antibody probe. Cells were pretreated with
10 µM MG132 for 2 hours, either alone or before treatment
with GA. Molecular weight markers are shown inkilodaltons.
(D) H1299 cells were treated with 0.1 µM GA for the indicated times, and cell lysates were analyzed for telomerase
activity by the TRAP assay. The lane labeled LB corresponds
to the negative control (lysis buffer only). ITAS represents the
internal telomerase assay standard. (E) Saos-2 cells transfected with Flag-hTERT or hTERT-HA or empty vector were
untreated or treated with 0.1 µM GA for 16 hours, and cell
lysates were analyzed for telomerase activity using the TRAP
assay.
FIG. 2. hTERT is ubiquitinated prior to proteasome-mediated degradation. (A) H1299 cells were co-transfected with
Flag-hTERT and HA-ubiquitin. Cells were either untreated
or treated for 2 hours with 10 µg/ml ALLnN or 0.1 µM GA, or
a combination of the two as specified above each lane. Immunoprecipitation was performed with anti-Flag antibody
before probing with anti-hTERT or anti-HA antibodies as
indicated besides each blot. Molecular weight markers are
shown in kilodaltons. (B) H1299 cells co-transfected with
Flag-hTERT and HA-ubiquitin were treated for 1 hour with
the GA concentration indicated in the presence of 10 µM
MG132. Immunoprecipitation was performed with anti-Flag
antibody followed by immunoblotting using an anti-HA antibody pro be. (C) H1299 cells co-transfected withFlag-hTERT
and HA-ubiquitin were either untreated or treated for 2 hours
with 10 µg/ml ALLnN as specified above each lane. Proteins
were immunoprecipated with anti-Flag antibody followed by
immunoblotting using an anti-HA antibody probe.
FIG. 3. MKRNl interacts withhTERT. (A) Analysis of the
physical interaction between hTERT and MKRNl using the
yeast two-hybrid assay. Five domains of hTERT were analyzed for binding to MKRNl. TRFl bait was used as a negative control. Blue signal on the SG-HWU/X plate indicates
activation of the reporter gene, Lacz. S, synthetic; G, galactose; H, histidine (-); W, tryptophan (-); U, uracil (-); X,
X-gal. (B) Schematic diagram of MKRNl domains. Amino
acid sequences (SEQ ID NOS 3-S, respectively in order of
appearance) surrounding the RING finger domain in MKRNl
and mutants used in this study. Cysteines and a histidine in the
RING finger domain are shown in red. Mutated residue in
MKRNlH3 o7 E is shown in blue. (C) H1299 cells co-transfected with hTERT-HA and MKRNl-VS were either
untreated or treated for 2 hours with 10 µg/ml ALLnN. AntiHA immunoprecipitates were analyzed by immunoblotting
using an anti-VS antibody probe. The left panel shows the
immunoblot of cell lysates (3% of the precipitated lysates)
probed with anti-VS antibody. hTERT-HA was visualized
with an anti-HA antibody probe. (D) H1299 cells co-transfected with Flag-hTERT and MKRNl-VS were either
untreated or treated for 2 hours with 10 µM MG132. AntiFlag immunoprecipitates were analyzed by immunoblotting
using an anti-VS antibody probe. The left panel shows the
immunoblot of cell lysates (3% of the precipitated lysates)
probed with anti-VS antibody. Flag-hTERT was visualized
with an anti-Flag antibody probe.

CROSS-REFERENCE TO RELATED
APPLICATIONS
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This application is related to U.S. Provisional application
Ser. No. 60/78S,414 filed Mar. 23, 2006, and claims priority to
such application under 3S USC §119.
BACKGROUND
Telomeres are essential and functional components of the
physical ends of eukaryotic chromosomes (Blackbum 1991 ;
Greider 1996). Telomeres enable cells to distinguish chromosome ends from double-strand breaks in the genome. Without
functional telomeres, the chromosomes are prone to nucleolytic degradation leading to cell death through apoptosis and
may rearrange by genetic recombination or end-to-end fusion
(Counter et al. 1992; Blasco et al. 1997; Artandi et al. 2002).
Most normal human somatic cells show a progressive loss of
telomeric DNA during successive rounds of cell division due
to a DNA end replication problem (Lingner et al. 199S). Thus,
telomere shortening has been proposed as a ticketing mechanism that controls the replicative capacity of cells and cellular
senescence (Harley 1991). Cells with extended replicative
life spans have mechanisms to counteract loss of telomeric
DNA. In most human cancer cells, telomere shortening is
alleviated by telomerase, a ribonucleoprotein enzyme that is
composed of a catalytic subunit, hTERT, and its template
RNA, hTR (Blackburn 1992; Counter et al. 1992). Telomerase activity is detectably expressed in the majority of
human cancer cells but is repressed in most normal somatic
cells (Kim et al. 1994). Since introduction ofhTERT gene
into normal somatic cells extends the life-span of the cells, the
immortalized phenotype of most cancer cells would involve
activation oftelomerase (Bodnar et al. 1998).
Telomerase activity correlates with hTERT expression,
implicating this catalytic subunit as the rate-limiting component of the telomerase holoenzyme (Nakamura and Cech
1998). Although telomerase activity is regulated by gene
expression for hTERT (Wang et al. 1998; Wu et al. 1999;
Meyerson et al. 1997), several lines of evidence have suggested a post-translational regulation of telomerase activity.
One possible mechanism for the post-translational modificati on oftelomerase is the interaction ofhTERTwith accessory
proteins such as enzymes, chaperones, and polypeptide modifiers (Lee et al. 2004; Liu 1999; Zhou and Lu 2001). Recent
studies have shown that the molecular chaperone Hsp90
binds specifically to hTERT to promote the assembly of
active telomerase both in a cell-free system and in intact cells
(Holt et al. 1999). Moreover, inhibition ofHsp90 function in
cells blocks assembly of active telomerase. However, the
underlying mechanism has not been elucidated.
Identifying cellular mechanisms that control the activity of
telomerases may provide new and helpful targets for establishing new cancer therapy agents.
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FIG. 1. hTERT is sensitive to the Hsp90 antagonist
geldanamycin. (A) Down-regulation of ectopically expressed
hTERT by GA. H1299 cells transfected with Flag-hTERT or
Flag-TRFl were treated with 0.1 µM GA for the indicated
times. Lysates were resolved on 8% SDS-PAGE and analyzed
by immunoblotting using an anti-Flag antibody probe. Cells
were pretreated with 10 µM MG132 or E-64 for 2 hours,
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FIG. 4. MKRNl functions as an E3 ubiquitin-ligase for
hTERT in vitro and in vivo. (A) HA-tagged hTERT (residues
946-1132) was incubated MKRNl or mutants in the presence
ofEl, E2, Hiscubiquitin (6xHis tag disclosed as SEQ ID NO:
7). Samples were resolved by 6% SDS-PAGE and analyzed
by immunoblotting with an anti-HA antibody probe. (B)
H1299 cells were co-transfected withFlag-hTERT, HA-ubiquitin, MKRNl-VS, and together with either MKRNlH3 o7 E_
VS or MKRNl ,i.c_ VS as specified. Cells were untreated or
treated with 10 µM MG132 for 2 hours. Anti-Flag immunoprecipitates and cell lysates were analyzed by immunoblotting with anti-HA antibody and anti-VS antibody probes,
respectively. (C) H1299 cells co-transfected with FlaghTERT and HA-ubiquitin, and together with or without
MKRNl-VS as indicated were treated with 10 µM MG132
for the indicated times. Anti-Flag immunoprecipitates and
cell lysates were analyzed by immunoblotting with anti-HA
antibody and anti-VS antibody probes, respectively.
FIG. 5. Overexpression ofMKRNl decreases telomerase
activity and telomere length. (A) HT1080 cells were stably
transfected with MKRNl-VS or an empty vector. The cells
were untreated or treated for 2 hours with 10 µMM G 13 2. Cell
lysates were analyzed by immunoblotting with anti-VS antibody probe. (B) Stable HTl 080 cell lines (MKRNl and vector) were harvested at 4S PD, and telomerase activities were
measured with different amounts of proteins using the TRAP
assay. The lane labeled LB corresponds to the negative control (lysis buffer only). ITAS represents the internal telomerase assay standard. (C) Cell lysates from stable HTl 080 cell
lines were analyzed by immunoprecipitation with antihTERT antibody followed by immunoblotting using same
antibody probe. (D) Representative results ofRT-PCR analysis forthe expression ofMKRNl, hTERT, andhTR in stable
HTl 080 cell lines. RT-PCR products from each sample were
normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) signal. (E) Stable HT1080 cell lines were harvested at 4S PD, and genomic DNA was digested with RsaI
and Hinfl, followed by Southern blotting using a telomere
repeat probe.

regulate MKRN-1 activity. A further embodiment of the subject invention pertains to methods of treating cancers by
administrating therapeutic agents that up-regulate MKRN-1
activity.
In reviewing the detailed disclosure which follows, and the
specification more generally, it should be borne in mind that
all patents, patent applications, patent publications, technical
publications, scientific publications, and other references referenced herein are hereby incorporated by reference in this
application in order to more fully describe the state of the art
to which the present invention pertains.
Reference to particular buffers, media, reagents, cells, culture conditions and the like, or to some subclass of same, is
not intended to be limiting, but should be read to include all
such related materials that one of ordinary skill in the art
would recognize as being of interest or value in the particular
context in which that discussion is presented. For example, it
is often possible to substitute one buffer system or culture
medium for another, such that a different but known way is
used to achieve the same goals as those to which the use of a
suggested method, material or composition is directed.
It is important to an understanding of the present invention
to note that all technical and scientific terms used herein,
unless defined herein, are intended to have the same meaning
as commonly understood by one of ordinary skill in the art.
The techniques employed herein are also those that are known
to one of ordinary skill in the art, unless stated otherwise. For
purposes of more clearly facilitating an understanding the
invention as disclosed and claimed herein, the following definitions are provided.
1. Screening Methods
The invention provides assays for screening test compounds which bind to or modulate the activity of an MKRN
polypeptide or bind to and inhibit or affect expression of an
MKRN polynucleotide. A test compound preferably binds to
an MKRN polypeptide. More preferably, a test compound
decreases or increases MKRN activity by at least about 10,
preferably about SO, more preferably about 7S, 90, or 100%
relative to the absence of the test compound.
1.1. Test Compounds
Test compounds relate to agents that potentially have therapeutic activity, i.e., bind to or modulate the activity of an
MKRN polypeptide or bind to or affect expression of an
MKRN polynucleotide. Test compounds can be pharmacologic agents already known in the art or can be compounds
previously unknown to have any pharmacological activity.
The compounds can be naturally occurring or designed in the
laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, test
compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not
limited to, biological libraries, spatially addressable parallel
solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound"
library method, and synthetic library methods using affinity
chromatography selection. The biological library approach is
limited to polypeptide libraries, while the other four
approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam,
Anticancer Drug Des. 12, 14S, 1997.
Methods for the synthesis of molecular libraries are well
known in the art (see, for example, DeWitt et al., Proc. Natl.
Acad. Sci. U.S.A. 90, 6909, 1993; Erb eta!. Proc. NatL.Acad.
Sci. U.S.A. 91, 11422, 1994; Zuckermann et al., J. Med.
Chem. 37, 2678, 1994; Cho et al., Science 261, 1303, 1993;
Carell et al., Angew. Chem. Int. Ed. Engl. 33, 20S9, 1994;
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DETAILED DESCRIPTION
The subject invention is based on the inventors discovery
that ubiquitination of telomerase is induced by a novel protein
MKRN-1. The up-regulation of MKRN-1 induces ubiquitination of one or more components of telomerase which
causes a degradation in telomerase activity. The degradation
of telomerase activity ultimately leads to degradation of
telomeres in the cells, and eventually cell death. Cells of many
types of cancers are known to be telomerase positive. Thus,
the inventors discovery enables the targeting ofMKRN-1 to
serve as a basis for novel cancer therapies.
Not being bound by any particular theory, the inventors
found that disruption of Hsp90 function by geldanamycin
(GA) promotes ubiquitination and proteasome-mediated
degradation of hTERT. Furthermore, they have identified a
novel hTERT binding protein MKRNl that functions as an E3
ligase and mediates ubiquitination ofhTERT in vivo and in
vitro. Overexpression of MKRNl in telomerase-positive
cells decreases telomerase activity and telomere length.
These observations indicate that MKRNl, a post-translational modifier ofhTERT, exerts a negative role in telomere
length homeostasis.
A particular embodiment of the subject invention pertains
to methods of screening for test compounds that modulate the
activity of MKRN-1 polypeptides. Another embodiment of
the subject invention pertains to therapeutic agents that up-
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Carell et al.,Angew. Chem. Int. Ed. Engl. 33, 2061; Gallop et
al., J. Med. Chem. 37, 1233, 1994).
1.2. High Throughput Screening
Test compounds can be screened for the ability to bind to
and up-regulate MKRN polypeptides orpolynucleotides or to
affect MKRN activity or MKRN gene expression using high
throughput screening. Using high throughput screening,
many discrete compounds can be tested in parallel so that
large numbers of test compounds can be quickly screened.
The most widely established techniques utilize 96-well
microtiter plates. The wells of the microtiter plates typically
require assay volumes that range from 50 to 500 µ!.In addition to the plates, many instruments, materials, pipettors,
robotics, plate washers, and plate readers are commercially
available to fit the 96-well format. Alternatively, "free format
assays," or assays that have no physical barrier between
samples, can be used.
1.3. Binding Assays
For binding assays, the test compound is preferably, but not
necessarily, a small molecule which binds to and occupies, for
example, the active site of the MKRN polypeptide, such that
normal biological activity is prevented. Examples of such
small molecules include, but are not limited to, small peptides
or peptide-like molecules, or non-peptide small molecules
such as organics identified by high throughput screens (e.g.,
chemical library screening).
In binding assays, either the test compound or the MKRN
polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label,
such as horseradish peroxidase, alkaline phosphatase, or
luciferase. Detection of a test compound which is bound to
the MKRN polypeptide can then be accomplished, for
example, by direct counting ofradioemmission, by scintillati on counting, or by determining conversion of an appropriate
substrate to a detectable product.
Those skilled in the art equipped with teachings herein will
appreciate that there are multiple conventional methods of
detecting binding of a test compound. For example, binding
of a test compound to a MKRN polypeptide can be determined without labeling either of the interactants. A microphysiometer can be used to detect binding of a test compound
with an MKRN polypeptide. A microphysiometer (e.g.,
CYTOSENSOR™) is an analytical instrument that measures
the rate at which a cell acidifies its environment using a
light-addressable potentiometric sensor (LAPS). Changes in
this acidification rate can be used as an indicator of the interaction between a test compound and an MKRN polypeptide
(McConnell et al., Science 257, 19061912, 1992).
In another alternative example, determining the ability of a
test compound to bind to an MKRN polypeptide can be
accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky,
Anal Chem. 63, 23382345, 1991, and Szabo et al., Curr. Opin.
Struct. Biol. 5, 699705, 1995). BIA is a technology for studying biospecific interactions in real time, without labeling any
of the interactants (e.g., BIAcore.™). Changes in the optical
phenomenon surface plasmon resonance (SPR) can be used
as an indication of real-time reactions between biological
molecules.
In yet another aspect of the invention, an MKRN polypeptide can be used as a "bait protein" in a two-hybrid assay or
three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos
et al., Cell 72, 223232, 1993; Madura et al., J. Biol. Chem.
268, 1204612054, 1993; Bartel et al., BioTechniques 14,
920924, 1993; Iwabuchi et al., Oncogene 8, 16931696, 1993;

and Brent W094/10300), to identify other proteins which
bind to or interact with the MKRN polypeptide and modulate
its activity.
In many screening embodiments, it may be desirable to
immobilize either the MKRN polypeptide (or polynucleotide) or the test compound to facilitate separation of bound
from unbound forms of one or both of the interactants, as well
as to accommodate automation of the assay. Thus, either the
MKRN polypeptide (orpolynucleotide) or the test compound
can be bound to a solid support. Suitable solid supports
include, but are not limited to, glass or plastic slides, tissue
culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex,
polystyrene, or glass beads). Any method known in the art can
be used to attach the MKRN polypeptide (or polynucleotide)
or test compound to a solid support, including use of covalent
and non-covalent linkages, passive absorption, or pairs of
binding moieties attached respectively to the polypeptide (or
polynucleotide) or test compound and the solid support. Test
compounds are preferably bound to the solid support in an
array, so that the location of individual test compounds can be
tracked. Binding of a test compound to a MKRN polypeptide
(or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels
include microtiter plates, test tubes, and microcentrifuge
tubes.
In a specific embodiment, the MKRN polypeptide may be
a fusion protein comprising a domain that allows the MKRN
polypeptide to be bound to a solid support. For example,
glutathione S-transferase fusion proteins can be adsorbed
onto glutathione sepharose beads (Sigma Chemical, St.
Louis, Mo.) or glutathione derivatized microtiter plates,
which are then combined with the test compound or the test
compound and the nonadsorbed MKRN polypeptide; the
mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and
pH). Following incubation, the beads ormicrotiterplate wells
are washed to remove any unbound components. Binding of
the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can
be dissociated from the solid support before binding is determined.
Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening
assays of the invention. For example, either a MKRN
polypeptide (or polynucleotide) or a test compound can be
immobilized utilizing conjugation of biotin and streptavidin.
BiotinylatedMKRN polypeptides (orpolynucleotides) or test
compounds can be prepared from biotinNHS(Nhydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce
Chemical). Alternatively, antibodies which specifically bind
to a MKRN polypeptide, polynucleotide, or a test compound,
but which do not interfere with a desired binding site, such as
the active site of the MKRN polypeptide, can be derivatized to
the wells of the plate. Unbound target or protein can be
trapped in the wells by antibody conjugation.
Methods for detecting such complexes, in addition to those
described above for the GST-immobilized complexes,
include immunodetection of complexes using antibodies
which specifically bind to the MKRN polypeptide or test
compound, enzyme-linked assays which rely on detecting an
activity of the MKRN polypeptide, and SDS gel electrophoresis under non-reducing conditions.
Screening for test compounds which bind to a MKRN
polypeptide or polynucleotide also can be carried out in an
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intact cell. Any cell which comprises a MKRN polypeptide or
polynucleotide can be used in a cell-based assay system. A
MKRN polynucleotide can be naturally occurring in the cell
or can be introduced using techniques such as those described
above. Binding of the test compound to a MKRN polypeptide
or polynucleotide is determined as described above.
1.4. EnzymeAssays
Test compounds can be tested for the ability to increase or
decrease the MKRN activity of a MKRN polypeptide.
MKRN activity can be measured, for example, by adapting
techniques such as that described in U.S. Pat. No. 4,529,693
(see Example 2). Enzyme assays can be carried out after
contacting either a purified MKRN polypeptide, a cell membrane preparation, or an intact cell with a test compound. A
test compound which decreases ligase activity of a MKRN
polypeptide by at least about 10, preferably about 50, more
preferably about 75, 90, or 100% is identified as a potential
therapeutic agent for decreasing MKRN activity. A test compound which increases ligase MKRN polypeptide by at least
about 10, preferably about 50, more preferably about 75, 90,
or 100% is identified as a potential therapeutic agent for
increasing MKRN activity.
1.5. Gene Expression
In another embodiment, test compounds which increase or
decrease MKRN gene expression are identified. An MKRN
polynucleotide is contacted with a test compound, and the
expression of an RNA or polypeptide product of the MKRN
polynucleotide is determined. The level of expression of
appropriate mRNA or polypeptide in the presence of the test
compound is compared to the level of expression of mRNA or
polypeptide in the absence of the test compound. The test
compound can then be identified as a modulator of expression
based on this comparison. For example, when expression of
mRNA or polypeptide is greater in the presence of the test
compound than in its absence, the test compound is identified
as a stimulator or enhancer of the mRNA or polypeptide
expression. Alternatively, when expression of the mRNA or
polypeptide is less in the presence of the test compound than
in its absence, the test compound is identified as an inhibitor
of the mRNA or polypeptide expression.
The level of MKRN mRNA or polypeptide expression in
the cells can be determined by methods well known in the art
for detecting mRNA or polypeptide. Either qualitative or
quantitative methods can be used. The presence of polypeptide products of an MKRN polynucleotide can be determined,
for example, using a variety of techniques known in the art,
including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined in vivo, in
a cell culture, or in an in vitro translation system by detecting
incorporation oflabeled amino acids into a MKRN polypeptide.
Such screening can be carried out either in a cell-free assay
system or in an intact cell. Any cell which expresses a MKRN
polynucleotide can be used in a cell-based assay system. The
MKRN polynucleotide can be naturally occurring in the cell
or can be introduced using techniques such as those described
above. Either a primary culture or an established cell line,
such as CHO or human embryonic kidney 293 cells, can be
used.
2. Pharmaceutical Compositions
The invention also pertains to pharmaceutical compositions comprising one or more therapeutic agents that are
identified by screening methods that utilize MKRN polypeptides and/or polynucleotides. Therapeutic agent(s) can be
administered to a patient to achieve a therapeutic effect, i.e.
useful cancer therapy. Pharmaceutical compositions of the

invention can comprise, for example, therapeutic agents identified by a screening method embodiment described herein,
which are identified by their ability to bind to or affect activity
of MKRN polypeptides, or bind to and/or affect expression
MKRN polynucleotides. The compositions can be administered alone or in combination with at least one other agent,
such as stabilizing compound, which can be administered in
any sterile, biocompatible pharmaceutical carrier, including,
but not limited to, saline, buffered saline, dextrose, and water.
The compositions can be administered to a patient alone, or in
combination with other agents, drugs or hormones.
In addition to the active ingredients, these pharmaceutical
compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which
facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical
compositions of the invention can be administered by any
number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal
means. Pharmaceutical compositions for oral administration
can be formulated using pharmaceutically acceptable carriers
well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to
be formulated as tablets, pills, dragees, capsules, liquids, gels,
syrups, slurries, suspensions, and the like, for ingestion by the
patient.
Further details on techniques for formulation and administration can be found in the latest edition ofREMINGTON'S
PHARMACEUTICAL SCIENCES (Maack Publishing Co.,
Easton, Pa., which is incorporated herein by reference). After
pharmaceutical compositions have been prepared, they can
be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include
amount, frequency, and method of administration.
This invention further pertains to the use of novel agents
identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a therapeutic agent identified as described herein in an appropriate
animal model. For example, an agent identified as described
herein (for example, but not limited to., a modulating agent,
an antisense nucleic acid molecule, a specific antibody,
ribozyme, or a MKRN polypeptide binding molecule) can be
used in an animal model to determine the efficacy, toxicity, or
side effects of treatment with such an agent. Furthermore, this
invention pertains to uses of novel agents identified by the
above described screening assays for treatments as described
herein.
Those skilled in the art will appreciate that numerous delivery mechanisms are available for delivering a therapeutic
agent to an area of need. By way of example, the agent may be
delivered using a liposome as the delivery vehicle. Preferably,
the liposome is stable in the animal into which it has been
administered for at least about 30 minutes, more preferably
for at least about 1 hour, and even more preferably for at least
about 24 hours. A liposome comprises a lipid composition
that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human.
A liposome useful in the present invention comprises a
lipid composition that is capable of fusing with the plasma
membrane of the targeted cell to deliver its contents to the
cell. Preferably, the transfection efficiency of a liposome is
about 0.5 µg of DNA per 16 nmole ofliposome delivered to
about 10 6 cells, more preferably about 1.0 µg of DNA per 16
nmole ofliposome delivered to about 10 6 cells, and even more
preferably about 2.0 µg of DNA per 16 nmol of liposome
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delivered to about 10 6 cells. Preferably, a liposome is between
about 100 and 500 nm, more preferably between about 150
and 450 nm, and even more preferably between about 200 and
400 nm in diameter.
Suitable liposomes for use in the present invention include
those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred
liposomes include liposomes having a polycationic lipid
composition and/or liposomes having a cholesterol backbone
conjugated to polyethylene glycol. Optionally, a liposome
comprises a compound capable of targeting the liposome to a
particular cell type, such as a cell-specific ligand exposed on
the outer surface of the liposome.
Complexing a liposome with a reagent such as an antisense
oligonucleotide or ribozyme can be achieved using methods
which are standard in the art (see, for example, U.S. Pat. No.
5,705,151). Preferably, from about 0.1 µg to about 10 µg of
polynucleotide is combined with about 8 nmol ofliposomes,
more preferably from about 0.5 µg to about 5 µg of polynucleotides are combined with about 8 nmol liposomes, and even
more preferably about 1.0 µg of polynucleotides is combined
with about 8 nmol liposomes.
In another embodiment, antibodies can be delivered to
specific tissues in vivo using receptor-mediated targeted
delivery. Receptor-mediated DNA delivery techniques are
taught in, for example, Findeis et al. Trends in Biotechnol. 11,
202-05 (1993); Chiou et al., GENE THERAPEUTICS:
METHODS AND APPLICATIONS OF DIRECT GENE
TRANSFER (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol.
Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269,
542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87,
3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991).
2.1 Determination of a Therapeutically Effective Dose
The determination of a therapeutically effective dose of
therapeutic agents identified by a screening method herein is
well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which attenuates or eliminates TB infection contrasted
to TB infection or attenuation that occurs in the absence of the
therapeutically effective dose.
Therapeutic efficacy and toxicity, e.g., ED 50 (the dose
therapeutically effective in 50% of the population) and LD 50
(the dose lethal to 50% of the population), can be determined
by standard pharmaceutical procedures in cell cultures or
experimental animals. The dose ratio of toxic to therapeutic
effects is the therapeutic index, and it can be expressed as the
ratio, LD 50/ED 50 .
The exact dosage will be determined by the practitioner, in
light of factors related to the subject that requires treatment.
Dosage and administration are adjusted to provide sufficient
levels of the active ingredient or to maintain the desired effect.
Factors which can be taken into account include the severity
of the disease state, general health of the subject, age, weight,
and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical
compositions can be administered every 3 to 4 days, every
week, or once every two weeks depending on the half-life and
clearance rate of the particular formulation.
Normal dosage amounts can vary from 0.1 to 100,000
micrograms, up to a total dose of about 1 g, depending upon
the route of administration. Guidance as to particular dosages
and methods of delivery is provided in the literature and
generally available to practitioners in the art. Those skilled in
the art will employ different formulations for nucleotides than

for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,
conditions, locations, etc.
Preferably, a therapeutic agent reduces expression of an
MKRN gene or the activity of an MKRN polypeptide by at
least about 10, preferably about 50, more preferably about 7 5,
90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of
expression of an MKRN gene or the activity of an MKRN
polypeptide can be assessed using methods well known in the
art, such as hybridization of nucleotide probes to MKRNspecific mRNA, quantitative RT-PCR, immunologic detection of an MKRN polypeptide, or measurement of MKRN
activity.
In any of the embodiments described above, any of the
pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic
agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art,
according to conventional pharmaceutical principles. The
combination of therapeutic agents can act synergistically to
effect the treatment or prevention of the various disorders
described above. Using this approach, one may be able to
achieve therapeutic efficacy with lower dosages of each
agent, thus reducing the potential for adverse side effects.
Any of the therapeutic methods described above can be
applied to any subject in need of such therapy.
3. Polypeptides
MKRN polypeptides according to the invention comprise
at least 12, 15,25, 50, 75, 100, 125, 150, 175,200,225,250
or 265 contiguous amino acids selected from the amino acid
sequence shown in SEQ ID NO: 2, or a biologically active
variant thereof, as defined below. A MKRN polypeptide of
the invention therefore can be a portion of an MKRN protein,
a full-length MKRN protein, or a fusion protein comprising
all or a portion of MKRN protein.
3.1 Biologically Active Variants
MKRN polypeptide variants which are biologically active,
i.e., confer an ability to initiate degradation ofhTERT, also
are considered MKRN polypeptides for purposes of this
application. Preferably, naturally or non-naturally occurring
MKRN polypeptide variants have amino acid sequences
which are at least about 55, 60, 65, or 70, preferably about 75,
80, 85, 90, 96, 96, or 98% identical to the amino acid sequence
shown in SEQ ID NO: 2 or a fragment thereof. Percent identity between a putative MKRN polypeptide variant and an
amino acid sequence of SEQ ID NO: 2 is determined using
the Blast2 alignment program (Blosum62, Expect 10, standard genetic codes).
Variations in percent identity can be due, for example, to
amino acid substitutions, insertions, or deletions. Amino acid
substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted
amino acid has similar structural and/or chemical properties.
Examples of conservative replacements are substitution of a
leucine with an isoleucine or valine, an aspartate with a
glutamate, or a threonine with a serine.
Amino acid insertions or deletions are changes to or within
an amino acid sequence. They typically fall in the range of
about 1 to 5 amino acids. Guidance in determining which
amino acid residues can be substituted, inserted, or deleted
without abolishing biological or immunological activity of an
MKRN polypeptide can be found using computer programs
well known in the art, such as DNASTAR software. Whether
an amino acid change results in a biologically active MKRN
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polypeptide can readily be determined by assaying for
MKRN activity, as described for example, in the specific
Examples, below.
3.2 Fusion Proteins
In some embodiments of the invention, it is useful to create
fusion proteins. By way of example, fusion proteins are useful
for generating antibodies against MKRN polypeptide amino
acid sequences and for use in various assay systems. For
example, fusion proteins can be used to identify proteins
which interact with portions of an MKRN polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or
phage display systems, can be used for this purpose. Such
methods are well known in the art and also can be used as drug
screens.
A MKRN polypeptide fusion protein comprises two
polypeptide segments fused together by means of a peptide
bond. For example, the first polypeptide segment can comprise at least 12, 15, 25, 50, 75, 100, 125, 150, 175, 200, 225,
or 250 contiguous amino acids of SEQ ID NO: 2 or of a
biologically active variant, such as those described above.
The first polypeptide segment also can comprise full-length
MKRN protein.
The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion
protein construction include galactosidase, glucuronidase,
green fluorescent protein (GFP), autofluorescent proteins,
including blue fluorescent protein (BFP), glutathione-Stransferase (GST), luciferase, horseradish peroxidase (HRP),
and chloramphenicol acetyltransferase (CAT). Additionally,
epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin
(HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD)
fusions, GAL4 DNA binding domain fusions, and herpes
simplex virus (HSY) BPI 6 protein fusions. A fusion protein
also can be engineered to contain a cleavage site located
between the MKRN polypeptide-encoding sequence and the
heterologous protein sequence, so that the MKRN polypeptide can be cleaved and purified away from the heterologous
moiety.
Many kits for constructing fusion proteins are available
from companies such as Promega Corporation (Madison,
Wis.), Stratagene (La Jolla, Calif.), CLONTECH (Mountain
View, Calif.), Santa Cruz Biotechnology (Santa Cruz, Calif.),
MBL International Corporation (MIC; Watertown, Mass.),
and Quantum Biotechnologies (Montreal, Canada; 1-888DNA-KITS).
3.3 Obtaining Polypeptides
MKRN polypeptides can be obtained, for example, by
purification of polypeptides from cells, expressing MKRN
polynucleotide(s) and other appropriate methods as will be
appreciated by those skilled in the art in view of the teachings
herein.
3.4 Protein Purification
MKRN polypeptides can be purified from any cell which
expresses the enzyme, including host cells which have been
transfected with MKRN enzyme expression constructs. A
purified MKRN enzyme polypeptide is separated from other
compounds which normally associate with the MKRN
enzyme polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art.
Such methods include, but are not limited to, size exclusion
chromatography, ammonium sulfate fractionation, ion
exchange chromatography, affinity chromatography, and preparative gel electrophoresis. A preparation of purified MKRN

polypeptides is at least 80% pure; preferably, the preparations
are 90%, 95%, or 99% pure. Purity of the preparations can be
assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.
4. Polynucleotides
An MKRN polynucleotide can be single- or doublestranded and comprises a coding sequence or the complement
of a coding sequence for an MKRN polypeptide. A coding
sequence for MKRN polypeptide of SEQ ID NO: 2 is shown
inSEQIDNO: 1.
Degenerate nucleotide sequences encoding MKRN
polypeptides, as well as homologous nucleotide sequences
which are at least about 50, 55, 60, 65, 60, preferably about
7 5, 90, 96, or 98% identical to the nucleotide sequence shown
in SEQ ID NO: 1 also are MKRN polynucleotides. Percent
sequence identity between the sequences of two polynucleotides is determined using computer programs such as
ALIGN which employ the FAS TA algorithm, using an affine
gap search with a gap open penalty of -12 and a gap extension
penalty of-2. Complementary DNA (cDNA) molecules, species homo logs, and variants ofMKRN polynucleotides which
encode biologically active MKRN polypeptides also are
MKRN polynucleotides.
4.1 Identification of Polynucleotide Variants and Homologs
Variants and homologs of the MKRN polynucleotides
described above also are MKRN polynucleotides. Typically,
homologous MKRN polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known
MKRN polynucleotides under stringent conditions, as is
known in the art. For example, using the following wash
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH
7.0), 0.1 % SDS, room temperature twice, 30 minutes each;
then 2xSSC, 0.1 % SDS, 50° C. once, 30 minutes; then
2xSSC, room temperature twice, 10 minutes each homologous sequences can be identified which contain at most about
25-30% basepair mismatches. More preferably, homologous
nucleic acid strands contain 15-25% basepair mismatches,
even more preferably 5-15% basepair mismatches.
Species homologs of the MKRN polynucleotides disclosed herein also can be identified by making suitable probes
or primers and screening cDNA expression libraries. It is well
known that the Tm of a double-stranded DNA decreases by
1-1.5° C. with every 1% decrease in homology (Bonner et al.,
J. Mo!. Biol. 81, 123 (1973 ). Variants of MKRN polynucleotides or polynucleotides of other species can therefore be
identified by hybridizing a putative homologous MKRN
polynucleotide with a polynucleotide having a nucleotide
sequence of SEQ ID NO: 1 or the complement thereof to form
a test hybrid. The melting temperature of the test hybrid is
compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.
Nucleotide sequences which hybridize to MKRN polynucleotides or their complements following stringent hybridization and/or wash conditions also are MKRN polynucleotides. Stringent wash conditions are well known and
understood in the art and are disclosed, for example, in Sambrook et al., MOLECULAR CLONING: A LABORATORY
MANUAL, rd ed., 1989, at pages 9.50-9.51.
Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen
that is approximately 12-20° C. below the calculated Tm of the
hybrid under study. The Tm of a hybrid between an MKRN
polynucleotide having a nucleotide sequence shown in SEQ
ID NO: 1 or the complement thereof and a polynucleotide
sequence which is at least about 50, preferably about 75, 90,
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96, or 98% identical to one of those nucleotide sequences can
be calculated, for example, using the equation of Bolton and
McCarthy, Proc. Natl. Acad. Sci. U.S.A. 48, 1390 (1962):

The control elements or regulatory sequences are those
nontranslated regions of the vector enhancers, promoters, 5'
and 3' untranslated regions which interact with host cellular
proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on
the vector system and host utilized, any number of suitable
transcription and translation elements, including constitutive
and inducible promoters, can be used. For example, when
cloning in bacterial systems, inducible promoters such as the
hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORTl plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin
promoter can be used in insect cells. Promoters or enhancers
derived from the genomes of plant cells (e.g., heat shock,
RUBISCO, and storage protein genes) or from plant viruses
(e.g., viral promoters or leader sequences) can be cloned into
the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it
is necessary to generate a cell line that contains multiple
copies of a nucleotide sequence encoding an MKRN
polypeptide, vectors based on SV40 or EBY can be used with
an appropriate selectable marker.
5. Host Cells
According to certain embodiments of the subject invention, an MKRN polynucleotide will need to be inserted into a
host cell, for expression, processing and/or screening. A host
cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed
MKRN polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Posttranslational processing which
cleaves a "prepro" form of the polypeptide also can be used to
facilitate correct insertion, folding and/or function. Different
host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g.,
CHO, HeLa, MDCK, HEK293, and W138), are available
from the American Type Culture Collection (ATCC; 10801
University Boulevard, Manassas, Va. 20110-2209) and can be
chosen to ensure the correct modification and processing of
the foreign protein.
Stable expression is preferred for long-term, high yield
production of recombinant proteins. For example, cell lines
which stably express MKRN polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements
and a selectable marker gene on the same or on a separate
vector. Following the introduction of the vector, cells can be
allowed to grow for 12 days in an enriched medium before
they are switched to a selective medium. The purpose of the
selectable marker is to confer resistance to selection, and its
presence allows growth and recovery of cells which successfully express the introduced MKRN sequences. Resistant
clones of stably transformed cells can be proliferated using
tissue culture techniques appropriate to the cell type. See, for
example, ANIMAL CELL CULTURE, R. I. Freshney, ed.,
1986.
5.1 Detecting Expression
A variety of protocols for detecting and measuring the
expression of a MKRN polypeptide, using either polyclonal
or monoclonal antibodies specific for the polypeptide, are
known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies
reactive to two non-interfering epitopes on a MKRN polypeptide can be used, or a competitive binding assay can be

Tm ~81.5° C.-16.6(log 10 [Na•])+0.41(% G+C)-0.63(%
formamide)-600/1),

where 1=the length of the hybrid in basepairs.
Stringent wash conditions include, for example, 4xSSC at
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC,
0.1 % SDS at 65° C. Highly stringent wash conditions include,
for example, 0.2xSSC at 65° C.
4.2 Preparation of Polynucleotides
A naturally occurring MKRN polynucleotide can be isolated free of other cellular components such as membrane
components, proteins, and lipids. Polynucleotides can be
made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification
technique, such as the polymerase chain reaction (PCR), or
by using an automatic synthesizer. Methods for isolating
polynucleotides are routine and are known in the art. Any
such technique for obtaining a polynucleotide can be used to
obtain isolated MKRN polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises MKRN nucleotide
sequences. Isolated polynucleotides are in preparations
which are free or at least 70, 80, or 90% free of other molecules.
MKRN DNA molecules can be made with standard
molecular biology techniques, using MKRN mRNA as a
template. MKRN DNA molecules can thereafter be replicated using molecular biology techniques known in the art
and disclosed in manuals such as Sambrook et al. (1989). An
amplification technique, such as PCR, can be used to obtain
additional copies of polynucleotides of the invention. The
inventors have successfully demonstrated this approach.
Alternatively, synthetic chemistry techniques can be used
to synthesizes MKRN polynucleotides. The degeneracy of
the genetic code allows alternate nucleotide sequences to be
synthesized which will encode a MKRN polypeptide having,
for example, an amino acid sequence shown in SEQ ID NO:
2 or a biologically active variant thereof.
4.3 Expression of Polynucleotides
To express a MKRN polynucleotide, the polynucleotide
can be inserted into an expression vector which contains the
necessary elements for the transcription and translation of the
inserted coding sequence. Methods which are well known to
those skilled in the art can be used to construct expression
vectors containing sequences encoding MKRN polypeptides
and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et al. (1989) and in Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley &
Sons, New York, N.Y., 1989.
A variety of expression vector/host systems can be utilized
to contain and express sequences encoding a MKRN enzyme
polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors;
yeast transformed with yeast expression vectors, insect cell
systems infected with virus expression vectors (e.g., baculovirus ), plant cell systems transformed with virus expression
vectors (e.g., cauliflower mosaic virus, CaMV; tobacco
mosaic virus, TMV) or with bacterial expression vectors
(e.g., Ti or pBR322 plasmids), or animal cell systems.
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employed. These and other assays are described in Hampton
et al., SEROLOGICAL METHODS: A LABORATORY
MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox et
al., J. Exp. Med. 158, 12111216, 1983).
5 .2 Expression and Purification of Polypeptides
Host cells transformed with nucleotide sequences encoding MKRN polypeptide can be cultured under conditions
suitable for the expression and recovery of the protein from
cell culture. The polypeptide produced by a transformed cell
can be secreted or contained intracellularly depending on the
sequence and/or the vector used. As will be understood by
those of skill in the art, expression vectors containing polynucleotides which encode MKRN polypeptides can be
designed to contain signal sequences which direct secretion
of soluble MKRN polypeptides through a prokaryotic or
eukaryotic cell membrane or which direct the membrane
insertion of membrane-bound MKRN polypeptide.
6. Antibodies
Antibodies are referenced herein and various aspects of the
subject invention utilize antibodies specific to MKRN
polypeptide(s ). As described above, one example of an therapeutic agent may pertain to an antibody. Any type of antibody
known in the art can be generated to bind specifically to an
epitope of an MKRN polypeptide. "Antibody" as used herein
includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab') 2 , andFv, which are capable
of binding an epitope of an MKRN polypeptide. Typically, at
least 6, 8, 10, or 12 contiguous amino acids are required to
form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or
50 amino acids.
An antibody which specifically binds to an epitope of an
MKRN polypeptide can be used therapeutically, as mentioned, as well as in immunochemical assays, such as Western
blots, ELISAs, radioimmunoassays, immunohistochemical
assays, immunoprecipitations, or other immunochemical
assays known in the art. Various immunoassays can be used to
identify antibodies having the desired specificity. Numerous
protocols for competitive binding or immunoradiometric
assays are well known in the art. Such immunoassays typically involve the measurement of complex formation
between an immunogen and an antibody which specifically
binds to the immunogen. Antibodies useful for embodiments
of the subject invention may be polyclonal, but are preferably
monoclonal antibodies.
7. Identification of Differentially Expressed Genes and Profiling of Cancers
To identify differentially expressed genes total RNA or,
preferably, mRNA is isolated from tissues of interest. For
example, RNA samples are obtained from tissues of experimental subjects and from corresponding tissues of control
subjects. Any RNA isolation technique that does not select
against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Ausubel et al.,
ed., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc. New York, 1987-1993. Large
numbers of tissue samples may readily be processed using
techniques well known to those of skill in the art, such as, for
example, the single-step RNA isolation process of Chomczynski, U.S. Pat. No. 4,843,155.
Transcripts within the collected RNA samples that represent RNA produced by differentially expressed genes are
identified by methods well known to those of skill in the art.
They include, for example, differential screening (Tedder et
al., Proc. Natl. Acad. Sci. U.S.A. 85, 208-12, 1988), subtractive hybridization (Hedrick et al., Nature 308, 149-53; Lee et
al., Proc. Natl. Acad. Sci. U.S.A. 88, 2825, 1984), and differ-

ential display (Liang & Pardee, Science 257, 967-71, 1992;
U.S. Pat. No. 5,262,311), andmicroarrays.
The differential expression information may itself suggest
relevant methods for the treatment of disorders involving
degradation of telomeres. For example, treatment may
include a modulation of expression of the differentially
expressed genes and/or the gene encoding the MKRN
polypeptides. The differential expression information may
indicate whether the expression or activity of the differentially expressed gene or gene product or the MKRN gene or
gene product are up-regulated or down-regulated.
Further, use of anti-MKRN antibodies can be used to
screen for tumors possessing varying expression of MKRN
polypeptides. As the characterization of tumors possessing
MKRN expression is elucidated, this information will be
useful in determining metastatic potential of a given tumor,
which in turn will assist in determining an appropriate treatment regime. Also, related to the foregoing, as drugs are
developed and identified that affect MKRN activity and/or
expression, screening of tumors will facilitate selection of
appropriate anti-cancer agents. Accordingly, another
embodiment of the invention pertains to a method of screening of a tumor cell for MKRN expression.
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The human lung carcinoma cell line H1299 was cultured in
RPMI-1640 medium, and the human fibrosarcoma cell line
HT1080 was cultured in Dulbecco's modified Eagle's
medium supplemented with 10% fetal bovine serum, 100
units/ml penicillin, and 100 µg/ml streptomycin in 5% co2 at
37° C. The human osteosarcoma cell line Saos-2 was maintained in McCoy's SA medium containing 15% fetal bovine
serum, 100 units/ml penicillin, and 100 µg/ml streptomycin.
To establish cell lines stably expressing MKRNl, the
MKRN1-V5 construct was transfected into HT1080 cells
using Lipofectamine Plus (Invitrogen, Carlsbad, Calif.)
according to the manufacturer's instructions. As a control,
HT1080 cells were also stably transfected with an empty
vector. Multiple independent single clones were isolated and
checked for protein expression by immunoblotting with antiV5 antibody.
Expression Vectors
The Flag-hTERT expression vector was constructed by
cloning the full-length hTERT cDNA into pCMV-Tag2 vector (Stratagene). The hTERT-HA expression vector (generously provided by H. Seimiya, Japanese Foundation for Cancer Research) has been described (Seimiya et al. 2000). The
MKRNl expression vector was constructed by inserting the
EcoRI and Natl fragment from the full-length MKRNl
cDNA (generated by PCR with the appropriate synthetic
primers) into pcDNA3.1 (Invitrogen, Carlsbad, Calif.). The
expression vector for GST-hTERT-HA was constructed by
cloning the fragment encoding the C-terminal region (amino
acid 946-1132) ofhTERT into pGEX-5X-2 (Amersham Biosciences Inc., Piscataway, N.J.). MKRNl and MKRNl
mutants were subcloned into pGEX-6P-1 for expression in
bacteria. The GST fusion proteins were expressed, purified,
and cleaved with PreScission™ protease to remove the
cleaved GST according to the manufacturer's instructions
(Amersham Biosciences Inc., Piscataway, N.J.).
Yeast Two-Hybrid Screening
Yeast two-hybrid screening was performed as described
(Lee et al. 2004). Briefly, the yeast strain EGY48 harboring
pLexA-hTERT (amino acid 946-1132) and pSH18-34 was
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transformed by the lithium acetate method with a HeLa
cDNA library fused to the activation domain vector pB42AD
(Clontech).
Immunoprecipitation and Immunoblotting
H1299 cells were transiently transfected with the expression vectors indicated in the figure legends using TransFast
transfection reagent (Promega, Madison, Wis.) according to
the manufacturer's instructions. Cells were lysed with buffer
containing 0.5% NP-40, 50 mM Tris-HCl (pH 7 .5), 150 mM
NaCl, 2 mM phenyl methylsulphonyl fluoride. After centrifugation at 12,000 rpm for 30 min, the supernatants were immunoprecipitated for 2 hours with anti-Flag (Sigma, St. Louis,
Mo.) or anti-HA (Santa Cruz biotechnology, Santa Cruz,
Calif.) antibodies and then incubated with Sepharose beads
conjugated to Protein G (Amersham Biosciences Inc., Piscataway, N.J.). When ubiquitin conjugates of hTERT were
detected, immunoprecipitation was performed with lysis
buffer containing 0.1 % SDS to dissociate its interacting proteins. Immunoblot analyses were performed using antihTERT (Santa Cruz biotechnology, Santa Cruz, Calif.), antiV5 (Invitrogen, Carlsbad, Calif.), anti-HA, and anti-Flag
antibodies.
In Vitro Ubiquitination Assay
GST-hTERT-HA expressed in bacteria was used as substrate for in vitro ubiquitination assay (Park et al. 2004). The
ubiquitination reactions were carried out in buffer (50 mM
Tris-HCl, pH 7.5, 2 mMATP, 2.5 mM MgC1 2 , 5 mM dithiothreitol, and 0.05% NP-40) containing yeast El (0.05 µg), E2
(0.2 µg), and Hiscubiquitin (0.8 µg) (6xHis disclosed as SEQ
ID NO: 7) in a final volume of 30 µ!. Purified wild-type or
mutant MKRNl as an E3 enzyme was added as indicated in
the figure legend. The reaction mixtures were incubated at
30° C. for 60 min and terminated with sample loading buffer
and run on SDS-PAGE. Slow migrating ubiquitin conjugates
were visualized by immunoblot analysis with anti-HA antibody.
Telomerase Assays
The telomeric repeat amplification protocol (TRAP) was
used as previously described (Kim et al. 2003). Cell extracts
(200 ng of protein) were added to telomerase extension reactions and incubated for 20 min at 37° C. Reactions were
stopped by heating at 94 ° C. for 90 seconds and placed on ice.
PCR was performed using the TS primer and ACX primer for
30 cycles (denaturation at 94 ° C. for 30 s, annealing at 60° C.
for 30 s, and extension at 72° C. for 30 s). As an internal
telomerase assay standard (ITAS), NT and TSNT primers
were added to the PCR mixture as previously described (Kim
and Wu 1997). Telomerase products were resolved by electrophoresis on a 12% nondenaturing polyacrylamide gel.
Bands were then visualized by staining with SYBR Green
(Molecular Probes, Eugene, Oreg.). The signal intensity was
quantified with a LAS-1000 Plus Image analyzer (Fuji Photo
Film, Tokyo, Japan).
Terminal Restriction Fragment (TRF) Analysis
To measure the telomere length, genomic DNA was
digested with RsaI and Hinfl and separated on 0.7% agarose
gel. DNA samples were transferred to a nylon membrane
(Hybond N+, Amersham Biosciences Inc., Piscataway, N.J.)
and hybridized with a 32 P labeled probe (TTAGGG) 20 (SEQ
ID NO: 6). Signals were detected by phosphoimage analyzer
(Fuji Photo Film, Tokyo, Japan).
hTERT is Sensitive to the Hsp90 Antagonist Geldanamycin
Inhibition ofHsp90 function by GA prevents the assembly
of active telomerase (Holt et al. 1999). Because GA mediates
the dissociation of Hsp90 from its client proteins and promotes rapid degradation by the proteasome (Goetz et al.
2003), the inventors believed that hTERT would be sensitive

to the Hsp90 antagonist. To investigate this possibility, the
inventors transfected H1299 cells with Flag-tagged hTERT
and assessed protein levels in the absence or presence of GA.
hTERT protein was highly expressed in untreated cells but
was down-regulated in a time-dependent manner in response
to GA treatment, with over 50% of the protein being eliminated within 2 hours of treatment (FIG. IA, lanes 1-5). TRFl
expression levels were not affected by GA treatment (FIG.
IA, middle blot). GA also decreased the level of hTERT
expression in a dose-dependent manner (FIG. IB). To verify
the ability of GA to down-regulate endogenous hTERT levels, H1299 cells were treated with GA and immunoblotted
using a polyclonal anti-hTERT antibody. Treatment of cells
with GA significantly decreased endogenous hTERT levels
(FIG. IC, upper blot).
The Hsp90 chaperone complex binds to hTERT and influences proper assembly with hTR to form an active enzyme
(Holt et al. 1999; Forsythe et al. 2001). The inventors tested
the influence of GA-induced degradation ofhTERT on telomerase activity in H1299 cells. Incubation with GA reduced
telomerase activity in a time-dependent manner (FIG. ID). To
more clearly determine the effects of GA on telomerase activity, N-terminal Flag-tagged hTERT and C-terminal
HA-tagged hTERT constructs were transfected to Saos-2
cells that lack detectable telomerase activity (Kim et al.
2003 ). The forced expression of exogenous hTERT produced
telomerase activity in these cells (FIG. IE). Furthermore,
incubation with GA reduced telomerase activity to near basal
levels. These results suggest that Hsp90 is not only important
for the proper conformation ofhTERT but also for maintaining telomerase assembly.
hTERT is Ubiquitinated and Degraded Via the Proteasomal
Pathway
Reduction in hTERT levels could be due to degradation
and/or turnover of the protein. To examine whether the GAmediated degradation of hTERT proceeds via the proteasome, the inventors pretreated H1299 cells for 2 hours with
the specific proteasome inhibitor, MG132, and subsequently
incubated with GA for 4 hours. Incubation of cells with
MG132 rescued the GA-induced down-regulation ofhTERT
(FIG. IA, lane 6 in upper blot) whereas pretreatment of cells
with the lysosomal proteolysis inhibitor E-64 had no effect on
hTERT levels (compare lanes 6 and 7). In the absence of GA
treatment, incubation of cells with either MG132 or E-64
alone did not cause a significant change in the levels of
hTERT expression relative to untreated controls (FIG. IA,
lanes 8 and 9 in upper blot). These results indicate that GAinduced down-regulation of hTERT is due to degradation
mediated by the proteasome pathway. The inventors also
demonstrate that endogenous hTERT levels are affected by
the proteasome pathway. Pretreatment of cells with MG 132
before treatment with GA rescued the proteasomal degradation of the endogenous hTERT protein (FIG. IC, lower blot).
GA-mediated protein degradation by the proteasome
depends on conjugation ofubiquitin to the Hsp90 client protein (Isaacs et al. 2002; Citri et al. 2002). To determine
whether hTERT is ubiquitinated in vivo prior to its degradation, H1299 cells co-transfected with Flag-tagged hTERT
and HA-tagged ubiquitin constructs were treated with GA,
ALLnN (a general proteasome inhibitor) or both. The immunoprecipitated products were evaluated by immunoblotting
with selected probes as described in FIG. 2. Treatment of GA
alone decreased hTERT levels; however, GA plus ALLnN
reversed this trend (FIG. 2A, compare lanes 3 and 4 in upper
blot). Treatment with ALLnN alone did not affect hTERT
levels relative to controls (FIG. 2A, compare lanes 1 and 2 in
upper blot). Note that the amount of high molecular weight
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smearing was more noticeable in the ALLnN-treated cells
(FIG. 2A, compare lanes 1 and 3 with lanes 2 and 4 in upper
blot). To confirm that these slower migrating bands represented ubiquitinated hTERT, anti-Flag immunoprecipitates
were probed with anti-HA antibody, which will illuminate
ubiquitin-modified hTERT (FIG. 2A, lower blot). Again,
ubiquitinated hTERT was dramatically elevated in the presence of the proteasome inhibitor ALLnN (FIG. 2A, compare
lanes 1 and 3 with lanes 2 and 4 in lower blot). These high
molecular smears are diagnostic for polyubiquitinated proteins (Gimta et al. 2003). This modification was substantially
enhanced by the treating cells with both ALLnN and GA
(FIG. 2A, compare lanes 2 and 4 in lower blot). In addition,
hTERT displayed enhanced GA-induced ubiquitination in a
dose-dependent manner in thepresenceofMG132 (FIG. 2B).
These data indicate that hTERT is ubiquitinated in
GA-treated cells prior to proteasome-dependent degradation
in a manner similar to other Hsp90 client proteins (Isaacs et al.
2002; Citri et al. 2002). Without being bound to any particular
theory, it is the inventors belief that two counteracting processes mediate hTERT levels: proteasomal degradation by
the ubiquitination pathway and rescue (or protection) from
degradation by Hsp90. The dynamic balance between these
two processes determines equilibrium levels of hTERT,
which then sets cellular telomerase activity. It is also worth
noting that polyubiquitinated hTERT forms were significantly elevated by ALLnN even in the absence of GA treatment (FIG. 2C, lanes S and 6). These results suggest that
hTERT is subject to ubiquitination even in the absence of GA.
Identification of a RING Finger Protein that Interacts with
hTERT
Ubiquitination is carried out by a cascade of reactions
catalyzed by ubiquitin-activating enzyme (El), ubiquitinconjugating enzyme (E2), and ubiquitin ligase (E3) (Hershko
et al. 1998; Pickart et al. 2001 ). E3 proteins are known to play
a pivotal role in determining the specificity of the system by
recognizing target substrates. The inventors established a
yeast two-hybrid system to search for an E3 ligase involved in
hTERT degradation. With the C-terminal domain ofhTERT
as bait (residues 946-1132), the inventors identified proteins
that interact with hTERT (FIG. 3A). One of the isolated
clones contains a C 3 HC4 -type RING finger domain that is
present in many E3 ubiquitin ligases (Joazeiro et al. 1999;
Levkowitz et al. 1999; Lorick et al. 1999). It was discovered
that the protein was identical to the Makorin ring finger protein 1 (MKRNl) (Gray et al. 2000). MKRNl is uniformly
expressed in all tissues and encodes a putative ribonucleoprotein with a distinctive array of zinc-finger motifs, including
four C 3 H zinc-finger motifs, an unusual Cys-His motif, and a
highly conserved RING finger domain (FIG. 3B). MKRNl
orthologs have been identified in a wide spectrum of species
(from invertebrates to vertebrates), suggesting an ancient origin of this highly conserved gene (Gray et al. 2000).
The physical interaction between MKRNl and hTERTwas
examined by co-immunoprecipitation experiments in cells
cotransfected with C-terminal HA-tagged hTERT and
MKRNl-VS expression vectors (FIG. 3C). The data show
that MKRNl was barely detectable in lysates directly probed
with anti-VS antibody (FIG. 3C, lanes 1 and3). This suggests
that MKRNl may be rapidly degraded through auto-ubiquitination like other ring finger proteins that promote their own
ubiquitination/degradation (Joazeiro and Weissman 2000). In
the presence of ALLnN, however, there was a significant
increase in both unmodified and ubiquitinated MKRNl species (FIG. 3C, lanes 2 and 4). Immunoprecipitation of cell
lysates with anti-HA antibody (hTERT) and subsequent
immunoblot analysis with anti-VS antibody (MKRNl)

revealed that hTERT co-immunoprecipitated with MKRNl
in cells treated with ALLnN but not in negative drug control
cells (FIG. 3C, compare lanes 7 and 8), suggesting that
hTERT binds to MKRNl in mammalian cells. When this
experiment was modified using N-terminal Flag-tagged
hTERT and MKRNl-VS expression vectors with a different
proteasome inhibitor (MG132), essentially identical results
were obtained (FIG. 3D).
MKRNl is an E3 Ubiquitin-Ligase that Enhances Ubiquitination ofhTERT
We next investigated the involvement ofMKRNl in ubiquitination ofhTERT. In vitro ubiquitination assays using purified components showed that the C-terminal domain (residues 946-1132) of hTERT was efficiently ubiquitinated by
wild-type MKRNl, but not by mutants MKRNlH3 o7 E or
MKRNl Ll.c (FIG. 4A). Thus, while MKRNl is an E3 ligase
for hTERT, mutating the RING finger domain destroys this
activity in vitro, indicating that the RING finger domain is
indispensable for E3 activity.
To investigate whether MKRNl contributes to the ubiquitination ofhTERT in vivo, Hl 299 cells were cotransfected with
Flag-hTERT, HA-ubiquitin, and MKRNl-VS constructs, and
immunoprecipitated with anti-Flag antibody followed by
immunoblotting with anti-HA antibody. Ubiquitin conjugates of hTERT were easily detected in the presence of
MG132 (FIG. 4B, lane 2 in upper blot). The amount ofubiquitinated hTERT was significantly reduced in cells cotransfected with MKRNl plus MKRNl H 3 o7 E (lane 6) compared to
cells transfected with MKRNl alone (lane 2) or in cells
cotransfected with MKRNl plus MKRNlLl.c (lane 4). These
data demonstrate that mutating the RING finger in
MKRNlH3 o7 E does not impair its ability to interact with
hTERT but disrupts the domain structure of the ubiquitin
ligase activity, thereby yielding a dominant negative phenotype. When the levels of ectopically expressed MKRNl and
mutants were examined, MKRNl expression was clearly
elevated by MG132 treatment (FIG. 4B, compare lanes 1 and
2 in lower blot). In contrast, MG132 had no effect on the
amount of MKRNl Ll.c (compare lanes 3 and 4), suggesting
that the deleted C-terminal region is required for auto-ubiqmtmation of MKRNl. When both MKRNl and
MKRNlH3 o7 E were cotransfected, we were able to detect
MKRNl H 3 o7 E in the absence of MG 132 although the expression level was slightly less (-2-fold) compared with that
elicited by the MG132 treatment (compare lanes S and 6).
Thus, mutating the histidine residue in the RING finger motif
inhibits auto-ubiquitination.
To examine the in vivo role ofMKRNl in ubiquitination of
hTERT, the inventors cotransfected H1299 cells with FlaghTERT plus HA-ubiquitin and immunoprecipitated with antiFlag antibody followed by immunoblotting with anti-HA
antibody. Although no hTERT-ubiquitin conjugates were
observed in untreated cells in this short exposed blot (FIG.
4C, lane 1 in upper blot), low levels were detected after 4S-60
minutes of MG132 treatment (lanes S and 6). In marked
contrast, co-expression of MKRNl caused a dramatic
increase in the amount of ubiquitinated hTERT species (lanes
7-12). When the expression levels ofMKRNl were examined
by immunoblotting with anti-VS antibody, both unmodified
and polyubiquitinated MKRNl species increased in a timedependent manner in response to MG 13 2 treatment (FIG. 4C,
lanes 7-12 in lower blot). On the basis of these data, the
inventors conclude that MKRNl is an E3 ligase for hTERT
ubiquitination in manmialian cells. Although our findings
show that MKRNl associates with and efficiently ubiquitinates hTERT, the foregoing data does not exclude the possibility of other E3 ligases for hTERT. The Hsp90/Hsp70-
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associated U-box ubiquitin ligase CHIP (carboxy terminus
Hsc70-interacting protein) may mediate the GA-stimulated
degradation of some Hsp90 client proteins (Connell et al.
2001; Meacham et al. 2001 ). Whether CHIP E3 activity regulates in vivo stability ofhTERT remains to be elucidated.
Overexpression of MKRNl Decreased Telomerase Activity
and Telomere Length.
Because MKRNl functions as an E3 ligase for hTERT
ubiquitination in vivo, the inventors examined whether
ectopic expression of MKRNl affects telomerase activity.
The inventors established HT! 080 cell lines stably expressing MKRNl (or an empty vector negative control). Levels of
ectopically expressed MKRNl were examined by immunoblotting with anti-VS antibody (FIG. SA). Treatment of
MG132 resulted in a substantial increase in MKRNl compared to untreated cells (compare lanes 3 and 6). Cells
expressing MKRNl and the empty vector grew normally and
exhibited no detectable differences in growth rates or morphology over 45 population doublings (PD). After 45 PD, the
inventors compared telomerase activity in stable cell lines
expressing MKRNl and the empty vector. Telomerase activity in cells expressing MKRNl was decreased by -5-fold
relative to the control cell line (FIG. SB). The overexpression
ofMKRNl resulted in a down-regulation of the endogenous
hTERTprotein(FIG. SC). These results suggestthatMKRNl
acts as a negative regulator oftelomerase. However, it is not
clear whether this decrease is due to a MKRNl-related
decrease in the expression of hTERT or hTR genes. To
address this possibility, the impact of MKRNl on gene
expression ofhTERT and hTR was evaluated using RT-PCR
analysis (Kim et al. 2002). Whereas MKRNl mRNA level
was -5-fold higher in cells expressing the gene (relative to
control cells), we observed no significant differences in
steady-state levels ofhTERT mRNA or hTR transcripts in cell
lines expressing MKRNl and the empty vector (FIG. SD). To
examine whether MKRNl-mediated decrease in telomerase
activity was attended by changes in telomere lengths, we
performed a terminal restriction fragment (TRF) size analysis
(Lee et al. 2004). Control cells exhibited an average telomere
length of -6 kb with most fragments spread over a range of
approximately 5 to 7 kb (FIG. SE). Telomeres were clearly
shortened in the clones expressing MKRNl with a decrease in
TRF length to -4 kb and spanning down to roughly 2.5 kb.
These findings suggest that MKRNl exerts a negative role in
telomere length maintenance and/or regulation.
The data presented herein demonstrates that MKRNl
markedly enhances hTERT ubiquitination in the absence of
GA treatment. This suggests that MKRNl functions as an E3
ligase for the constitutive ubiquitination of mature hTERT
assembled with hTR in the nucleus when the molecular chaperone Hsp90 is intact. Additionally, MKRNl may perform
this same function with newly synthesized hTERT in cytoplasm. Ubiquitination of hTERT may be regulated by
changes in the expression and activity of MKRNl and deubiquitinating enzymes. Moreover, continued expression of
MKRNl in telomerase-positive cells resulted in a decrease in
telomerase activity and cells with shortened telomeres. Thus,
MKRNl regulates telomerase activity and telomere length
through dynamic control of hTERT protein stability. The
function oftelomerase during development, aging, and cancer has been extensively studied (Kim et al. 2002). MKRNl,
a post-translational modifier ofhTERT, may play an important role in telomere length maintenance and/or regulation
through ubiquitin-mediated proteolysis ofhTERT.

Example 2
Identification ofhMKRNl Interactive Factors by
Yeast Two-Hybrid Screening
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Yeast two-hybrid screens similar to that described in
Example 1 are implemented, except instead of screening with
pLexA-hTERT, pLexA-MKRNl with the same HeLa cDNA
library fused to the activation domain vector pB42AD
(Clonetech) is used. This will allow identification additional
protein partners for MKRNl E3 ubiquitin ligase.
Prior to setting up the system with MKRN as bait, autoactivation MKRNl in yeast is checked, since it must be verified
that DNA binding fusions with MKRN do not activate transcription alone. To ensure that the MKRNl-DNA binding
fusion proteins are behaving correctly (eg., properly folded),
a known positive couple (hTERT as prey and MKRNl as bait)
is verified. The inventors showed that hTERT 946 - 1132 gave a
strong positive Lacz signal with WT hMKRNl prey; therefore, reversing the partners will give concordant results if the
MKRNl is a functional partner. In fact, for any subsequent
positives obtained by 2-hybrid screening described below, we
will perform a reciprocal swap like this to ensure concordance. Note also that screening with libraries selects for optimized interactions. It is known, for example that subdomains
may interact better than whole proteins (probably reflects
domain folding, stearic access and so forth). For this reason,
our original screening using hTERT as bait (FIG. 3) was
successful with a domain spanning residues 946-1132 of
hTERT. It is reasonable to propose a similar approach using
MKRNl as bait. The 482 amino acid hMKRNl are divided
into subclone domains in the pLexA-MKRNl bait. Positive
and negative controls (hTERT and TRFl respectively) are
used. As shown in xx FIG. 12, we will prepare a series of
intact as well as overlapping and non-overlapping clones. The
domain organization of hMKRNl is useful in selecting the
appropriate clones. For example, domain analysis by "NCBI
Conserved Domain Search" algorithm reveals that
hMKRNl 132- 240 contains a strong homology to RecQ helicase. Given the conservation ofMKRNl (Reprint #1 ), it may
have other activities and targets that are unrelated to the
ubiquitin-proteasome pathway. Moreover, the RecQ domain
should not be affected by a single residue change in the RING
finger at H307; thus the hMKRNlH3 0 7 E mutant should be
able to bind these targets in the absence ofE3 ubiquitin ligase
function. All of these constructs may be subcloned,
sequenced and checked for their ability to couple with
hTERT 946 - 1132 using the 2-hybrid assay. These data enable
sorting out other positives since the regions of binding
betweenhTERT/MKRN are established; thus, any new genes
found to interact with non-hTERT binding sites signify a
novel partner proteins (for example binding partners in RecQ
helicase).
Characterization of Specificity
Positives are characterized similar to the strategies
described in Example 1. Depending on the number of positives, different approaches are taken. For example, a limited
number of positives are obtained involving only a few of our
bait constructs, a new transformation with positive and negative controls (including empty vectors) is repeated and reassayed for specificity, bait swaps and then sequenced. If a
larger number of positives (50-100) are obtained, direct
sequence analysis is conducted. Blast search characterizations for known proteins, conserved domains and homology
with existing genes and gene products, are conducted see
Example 1. Sequence data may be analyzed. For example,
genes not in frame with the activation domain, indications of
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gene inversions (polyAAA tail position), genes encoding
RNA or retroposons would be less interesting.
Positive interactions is also confirmed outside the yeast
system. In brief, pull downs and Co-IP experiments in a
model cell system (such as HeLa cells which express low
levels ofMKRNl and HEK293 cells expressing high levels of
MKRNl) are performed. Co-localization using immunofluorescence and confocal microscopy to validate the 2-hybrid
couple in mammalian cells may also be performed.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS,
<210>
<211>
<212>
<213>

7

SEQ ID NO 1
LENGTH, 3025
TYPE, DNA
ORGANISM, Homo sapiens

<400> SEQUENCE,

1

gaacgggtgc ctcagtgtcc ttcccctccc ctcgcctggc ctcgcgtcct ctccccgcag

60

ccggaccgga actatgtgat cccggaagtt ccgggccttt gctgtgtggg ataaacagta

120

atggcggagg ctgcaactcc cggaacaaca gccacaacat caggagcagg agcggcagcg

180

gcgacggcgg cagcagcctc ccccaccccg atccccacag tcaccgcccc gtccctgggg

240

gcgggcggag ggggcggcgg cagcgacggc agcggcggcg gctggactaa acaggtcacc

300

tgcaggtatt ttatgcatgg ggtttgtaag gaaggagaca actgtcgcta ctcgcatgac

360

ctctctgaca gtccgtatag tgtagtgtgc aagtattttc agcgagggta ctgtatttat

420

ggagaccgct gcagatatga acatagcaaa ccattgaaac aggaagaagc aactgctaca

480

gagctaacta caaagtcatc ccttgctgct tcctcaagtc tctcatcgat agttggacca

540

cttgttgaaa tgaatacagg cgaagctgag tcaagaaatt caaactttgc aactgtagga

600

gcaggttcag aggactgggt gaatgctatt gagtttgttc ctgggcaacc ctactgtggc

660

cgtactgcgc cttcctgcac tgaagcaccc ctgcagggct cagtgaccaa ggaagaatca

720

gagaaagagc aaaccgccgt ggagacaaag aagcagctgt gcccctatgc tgcagtggga

780

gagtgccgat acggggagaa ctgtgtgtat ctccacggag attcttgtga catgtgtggg

840

ctgcagctcc tgcatccaat ggatgctgcc cagagatcgc agcatatcaa atcgtgcatt

900

gaggcccatg agaaggacat ggagctctca tttgccgtgc agcgcagcaa ggacatggtg

960

tgtgggatct gcatggaggt ggtctatgag aaagccaacc ccagtgagcg ccgcttcggg

1020

atcctctcca actgcaacca cacctactgt ctcaagtgca ttcgcaagtg gaggagtgct

1080

aagcaatttg agagcaagat cataaagtcc tgcccagaat gccggatcac atctaacttt

1140

gtcattccaa gtgagtactg ggtggaggag aaagaagaga agcagaaact cattctgaaa

1200

tacaaggagg caatgagcaa caaggcgtgc aggtattttg atgaaggacg tgggagctgc

1260
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28
-continued

ccatttggag ggaactgttt ttacaagcat gcgtaccctg atgccggtag agaggagcca

1320

cagagacaga aagtgggaac atcaagcaga taccgggccc aacgaaggaa ccacttctgg

1380

gaactcattg aggaaagaga gaacagcaac ccctttgaca acgatgaaga agaggttgtc

1440

acctttgagc tgggcgagat gttgcttatg cttttggctg caggtgggga cgacgaacta

1500

acagactctg aagatgagtg ggacttgttt catgatgagc tggaagattt ttatgacttg

1560

gatctatagc aaccttgcgt ggcgtgtgaa ctggtctgct gacctcagac agcagctgtc

1620

ccctgtggtg gtgtggcagt cctgttgttc tctcctaggc aggcctctca actccaggtg

1680

ctgtcctaag aatttttacc cagggcctgt cttctcaacc cctcaccttt ccctgaggag

1740

tgtgttgttt tccctgttga aaaaagttac aaaaataaat cttaaagtta gttttttgta

1800

acacgaattt aactgtcaga cagttagtgt aagtgtgttg cgtcatctgt tttcaaccag

1860

attgcattta tggacttttc acacactcat tttgaggacc ccaggttcaa aagtaaaagc

1920

actggccctg ctttggggtc caagaatagg agtgatgggt gaagggacct aacctggcca

1980

atagccctct gccccacaca tgggatgtgg atccttgacg tttctggtga aatctgcaca

2040

tctgtgtttt tatatctgtt ccctaccctg taatccctac cacgtgcact tgttctgtgg

2100

ttttggtctc ttgtttaatt gcacacaagt aatactactg ggtaaccaga atcaggtgtg

2160

aatgtgttga gattttttac tgttttgcat gataggaaaa ttgaaaaaga atacgtataa

2220

aagatagaga ggcataacat caatgcagag ttggaagttg gctcccaagg gctgacatgg

2280

tgtgagtgtg tgggtgtgtg ataagcttct catccctgca tagatgcagt attcttagcc

2340

ttagtagaaa aacctggttt agtggtttaa gccttgtgtg gcaaatagat cttaaagggc

2400

aaagcagtat attggtagtt gtcaatatag cagtgctagc tctgtctata taaatagaga

2460

aatggggtta gccatagagg ttaaaactac ctggttatcc catataataa cacaaactgg

2520

gtcttggata cacagttgta tttaatgttt tacgatctac cctttccagt acaggcactt

2580

tctgagaaac ctttgtcctc acttgaggca ttttgttgtc gggtttttgt gtttgttttt

2640

gtgggtattt gcctcattcc acccctgagc tttcaggtag acagacgtga ttcaaaactc

2700

tgttctaagg tgtttattgt agtggagtaa tgggtttgca gtgataagtc atacttttcc

2760

accgaaaggg agggcttggg aatccctgag attagctaaa gttaagttgt tggagaattc

2820

cttgattgga aattgtacct ttgtgttttg ttgctctgtt tcctgaaaat aactcgggga

2880

tgctcctggt ttgtccatct actgctttga ttccttggat cccacccatt ctttcacttt

2940

aagaaaaaac aaataattgt tgcagaggtc tctgtatttt gcagctgccc ttttgtaaga

3000

agcacttttc ccaaataaaa caatt

3025

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 482
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 2
Met Ala Glu Ala Ala Thr Pro Gly Thr Thr Ala Thr Thr Ser Gly Ala
1
5
10
15
Gly Ala Ala Ala Ala Thr Ala Ala Ala Ala Ser Pro Thr Pro Ile Pro
20
25
30
Thr Val Thr Ala Pro Ser Leu Gly Ala Gly Gly Gly Gly Gly Gly Ser
35
40
45
Asp Gly Ser Gly Gly Gly Trp Thr Lys Gln Val Thr Cys Arg Tyr Phe
50
55
60
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30
-continued

Met His Gly Val Cys Lys Glu Gly Asp Asn Cys Arg Tyr Ser His Asp
65

70

75

80

Leu Ser Asp Ser Pro Tyr Ser Val Val Cys Lys Tyr Phe Gln Arg Gly
85

90

95

Tyr Cys Ile Tyr Gly Asp Arg Cys Arg Tyr Glu His Ser Lys Pro Leu
100

105

110

Lys Gln Glu Glu Ala Thr Ala Thr Glu Leu Thr Thr Lys Ser Ser Leu
115

120

125

Ala Ala Ser Ser Ser Leu Ser Ser Ile Val Gly Pro Leu Val Glu Met
130

135

140

Asn Thr Gly Glu Ala Glu Ser Arg Asn Ser Asn Phe Ala Thr Val Gly
145

150

155

160

Ala Gly Ser Glu Asp Trp Val Asn Ala Ile Glu Phe Val Pro Gly Gln
165

170

175

Pro Tyr Cys Gly Arg Thr Ala Pro Ser Cys Thr Glu Ala Pro Leu Gln
180

185

190

Gly Ser Val Thr Lys Glu Glu Ser Glu Lys Glu Gln Thr Ala Val Glu
195

200

205

Thr Lys Lys Gln Leu Cys Pro Tyr Ala Ala Val Gly Glu Cys Arg Tyr
210

215

220

Gly Glu Asn Cys Val Tyr Leu His Gly Asp Ser Cys Asp Met Cys Gly
225

230

235

240

Leu Gln Leu Leu His Pro Met Asp Ala Ala Gln Arg Ser Gln His Ile
245

250

255

Lys Ser Cys Ile Glu Ala His Glu Lys Asp Met Glu Leu Ser Phe Ala
260

265

270

Val Gln Arg Ser Lys Asp Met Val Cys Gly Ile Cys Met Glu Val Val
275

280

285

Tyr Glu Lys Ala Asn Pro Ser Glu Arg Arg Phe Gly Ile Leu Ser Asn
290

295

300

Cys Asn His Thr Tyr Cys Leu Lys Cys Ile Arg Lys Trp Arg Ser Ala
305

310

315

320

Lys Gln Phe Glu Ser Lys Ile Ile Lys Ser Cys Pro Glu Cys Arg Ile
325

330

335

Thr Ser Asn Phe Val Ile Pro Ser Glu Tyr Trp Val Glu Glu Lys Glu
340

345

350

Glu Lys Gln Lys Leu Ile Leu Lys Tyr Lys Glu Ala Met Ser Asn Lys
355

360

365

Ala Cys Arg Tyr Phe Asp Glu Gly Arg Gly Ser Cys Pro Phe Gly Gly
370

375

380

Asn Cys Phe Tyr Lys His Ala Tyr Pro Asp Ala Gly Arg Glu Glu Pro
385

390

395

400

Gln Arg Gln Lys Val Gly Thr Ser Ser Arg Tyr Arg Ala Gln Arg Arg
405

410

415

Asn His Phe Trp Glu Leu Ile Glu Glu Arg Glu Asn Ser Asn Pro Phe
420

425

430

Asp Asn Asp Glu Glu Glu Val Val Thr Phe Glu Leu Gly Glu Met Leu
435

440

445

Leu Met Leu Leu Ala Ala Gly Gly Asp Asp Glu Leu Thr Asp Ser Glu
450

455

460

Asp Glu Trp Asp Leu Phe His Asp Glu Leu Glu Asp Phe Tyr Asp Leu
465

Asp Leu

470

475

480
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-continued

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 54
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 3
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu
1
5
10
15
Arg Arg Phe Gly Ile Leu Ser Asn Cys Asn His Thr Tyr Cys Leu Lys
20
25
30
Cys Ile Arg Lys Trp Arg Ser Ala Lys Gln Phe Glu Ser Lys Ile Ile
35
40
45
Lys Ser Cys Pro Glu Cys
50

<210>
<211>
<212>
<213>

SEQ ID NO 4
LENGTH, 54
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 4
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu
1
5
10
15
Arg Arg Phe Gly Ile Leu Ser Asn Cys Asn Glu Thr Tyr Cys Leu Lys
20
25
30
Cys Ile Arg Lys Trp Arg Ser Ala Lys Gln Phe Glu Ser Lys Ile Ile
35
40
45
Lys Ser Cys Pro Glu Cys
50

<210>
<211>
<212>
<213>

SEQ ID NO 5
LENGTH, 20
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 5
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu
1
5
10
15
Arg Arg Phe Gly
20

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH, 120
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
probe

<400> SEQUENCE,
ttagggttag ggttagggtt agggttaggg ttagggttag ggttagggtt agggttaggg

60

ttagggttag ggttagggtt agggttaggg ttagggttag ggttagggtt agggttaggg

120

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
6xHis tag
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33
-continued
<400> SEQUENCE, 7

His His His His His His
1

5

What is claimed is:
1. A method for isolating and identifying a potential can- 10

didate for affecting activity oftelomerase in telomerase positive cancer cells; said method comprising

(i) applying a yeast-two-hybrid procedure in which a bait
vector carries a polynucleotide sequence encoding a bait
MKRN polypeptide, wherein said MKRN polypeptide
comprises SEQ ID NO. 2, and a prey vector carries a
sequence from a cDNA or genomic DNA library encoding a prey polypeptide;

15

(ii) transforming yeast host cells with said first and second
20
hybrid vectors;
(iii) isolating positive transformed cells;

(iv) extracting second hybrid vector from said positive
transformed cells to obtain a sequence encoding an
interacting protein which binds to said MKRN polypeptide expressed by said first hybrid vector; and
(v) identifying a potential candidate for affecting activity
of telomerase in telomerase positive cancer cells by further identifying from the interacting polypeptide
obtained from step (iv) the polypeptide that modulates
the expression or activity of said MKRN polypeptide;
whereby the identified polypeptide that modulates the
expression or activity of said MKRN polypeptide is the
potential candidate for affecting activity oftelomerase in
telomerase positive cancer cells.

* * * * *

